Opinion|Videos|May 20, 2024
Utilization of Neuroimaging in Alzheimer’s Disease
Key opinion leaders emphasize the importance of neuroimaging in Alzheimer's disease, as it can rule out different diseases and diagnose microbleeds, while also discussing which biomarkers, histopathological features, and imaging characteristics are associated with different stages of the disease, exploring whether these tools can provide insights into the true onset of Alzheimer's disease.
Advertisement
Episodes in this series
- Describe the use of neuroimaging in AD.
- Which imaging features are associated with different stages of Alzheimer’s disease?
Can they tell us when Alzheimer’s disease really starts?
Advertisement
Related to this article
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
3
Previewing Advancements in Hypersomnia Diagnosis and Treatment
4
Topline Phase 2 ADDRESS-LC Data Show Subgroup Benefit for Bezisterim in Long COVID
5